Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

  • In development
  • GID-TA11422
  • Expected publication date: TBC

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6363